Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
University of Virginia
Mayo Clinic
University of California, San Francisco
Eli Lilly and Company
City of Hope Medical Center
Syros Pharmaceuticals
Case Comprehensive Cancer Center
Gilead Sciences
Celgene
University of Chicago
Incyte Corporation
Masonic Cancer Center, University of Minnesota
Northwestern University
Altor BioScience
Piramal Enterprises Limited
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Center, Korea